1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6464A7E9698CAFE78002585C7003CC6CA
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-medical-affairs-hematology-product-launches-timeline-resources-preparedness?opendocument
18
19opendocument
203.237.186.116
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Launch Optimization

Maximizing the Impact of Medical Affairs in Hematology Product Launches: Timeline, Resources, and Preparedness

ID: 5628


Features:

20 Info Graphics

9 Data Graphics

160+ Metrics


Pages/Slides: 40


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Medical Affairs in Hematology Product Launches: Timeline, Resources, and Preparedness”

STUDY OVERVIEW

With competition keen among pharma companies to successfully launch new hematology products in a timely manner, organizations are turning to their medical experts to support launches. As a key conduit between pharma companies and key opinion leaders, Medical Affairs has become one of the key players in hematology product launches.

In order to maximize hematology launch impact, Medical Affairs groups need to develop and maintain a strategic timeline for launch activities; deploy resources at appropriate points in this timeline; and ensure that launch preparedness metrics are used to ensure activities adhere to the timeline - all of which can help determine the ultimate success of a new hematology product.

Best Practices, LLC conducted this benchmarking research to explore how Medical Affairs can maximize its hematology launch impact. This study provides insights and benchmarks around staffing, budgeting, timeline, preparedness metrics, tools and technology for an effective hematology launch. It also highlights the critical success factors and pitfalls for Medical Affairs during hematology launch.

KEY TOPICS

  • Hematology launch timeline overview
  • Hematology launch resourcing
  • Hematology launch enablers

KEY METRICS
  • Please indicate the time when each Medical Affairs group ideally should get involved in hematology product launch activities and when each group actually becomes involved
  • Indicate the percentage of total Medical Affairs launch budget allocated to each of the listed activities
  • Indicate the percentage of total Medical Affairs staffing allocated to each of the listed activities
  • Have you developed a launch dashboard to measure the value and impact of Medical Affairs role in hematology launch success and to monitor launch progress?
  • In your experience, what have been the critical success factors that drive successful hematology launches for Medical Affairs?
  • What are the major pitfalls for Medical Affairs during hematology product launches?

SAMPLE KEY FINDINGS
  • Put in place a feedback loop to leverage insights from the field to influence brand team’s activities:

    Generate insights around drug and competition. Translate these insights into tactical actions. Adjust launch preparation based on this intel. Medical Affairs’ access to the field is a tool it can leverage to influence other functions and change the launch strategy.


METHODOLOGY

Best Practices, LLC engaged 19 hematology Medical Affairs experts from 14 pharmaceutical and biotechnology companies in this research study through a benchmarking survey, interviews and a roundtable discussion.


Industries Profiled:
Pharmaceutical; Biotech; Chemical; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Celgene; Crescendo Bioscience; Curis; Daiichi Sankyo; Grifols; Orchard Therapeutics; Roche; Sandoz; Sanofi; Servier; Shire; Takeda Pharmaceuticals; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.